Literature DB >> 8439659

Bacterial biofilm, brown pigment stone and blockage of biliary stents.

J Y Sung1, J W Leung, E A Shaffer, K Lam, J W Costerton.   

Abstract

Bacterial pathogens gain access into the biliary system by descending via the portal venous circulation or ascending through the sphincter of Oddi in duodenal-biliary reflux. Bacteria thrive as glycocalyx-enclosed microcolonies, coalescing to form an adherent biofilm. The establishment of biofilm is a key event in the formation of biliary sludge and pigment gallstones, and the blockage of biliary stents. The biofilm mode of growth is very effective because it provides bacteria with a measure of protection from antibacterial agents and phagocytic leucocytes. Calcification of the matrix confers further protection for the micro-organisms living inside the biofilm. To date, attempts to prevent blockage of biliary stent have employed physical methods by using large self-expandable stents and stents without side hole. Incorporation of antibiotics within stents has not been successful presumably because bacteria once living in their biofilm are quite resistant to antimicrobial agents. Even the most toxic bile salts have no effect on the biofilm bacteria. Yet, hydrophobic bile salts reduce bacterial adhesion on biomaterial, suggesting that incorporation of such bile salts might prevent the formation of bacterial biofilm.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439659     DOI: 10.1111/j.1440-1746.1993.tb01171.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  26 in total

1.  Therapeutic endoscopy. Recent advances.

Authors:  S C Chung
Journal:  Surg Endosc       Date:  1999-07       Impact factor: 4.584

2.  Metallic biliary stents for malignant obstructive jaundice:a review.

Authors:  Richard A Kozarek
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

3.  Nitinol biliary stent versus surgery for palliation of distal malignant biliary obstruction.

Authors:  Rodrigo Castaño; Tercio L Lopes; Oscar Alvarez; Victor Calvo; Leticia P Luz; Everson L A Artifon
Journal:  Surg Endosc       Date:  2010-02-21       Impact factor: 4.584

Review 4.  The current standard of care in the periprocedural management of the patient with obstructive jaundice.

Authors:  D L Clarke; Y Pillay; F Anderson; S R Thomson
Journal:  Ann R Coll Surg Engl       Date:  2006-11       Impact factor: 1.891

Review 5.  Plastic biliary stent occlusion: factors involved and possible preventive approaches.

Authors:  Gianfranco Donelli; Emilio Guaglianone; Roberta Di Rosa; Fausto Fiocca; Antonio Basoli
Journal:  Clin Med Res       Date:  2007-03

6.  What is amniotic fluid 'sludge'?

Authors:  R Romero; J P Kusanovic; J Espinoza; F Gotsch; C L Nhan-Chang; O Erez; C J Kim; N Khalek; P Mittal; L F Goncalves; C Schaudinn; S S Hassan; J W Costerton
Journal:  Ultrasound Obstet Gynecol       Date:  2007-10       Impact factor: 7.299

Review 7.  Antireflux biliary stents: are they the solution to stent occlusions?

Authors:  D Nageshwar Reddy; Rupa Banerjee; Ong Wai Choung
Journal:  Curr Gastroenterol Rep       Date:  2006-04

Review 8.  Endoscopic stenting for palliation of malignant biliary obstruction. A review of progress in the last 15 years.

Authors:  J J Sung; S C Chung
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

9.  Multicenter study evaluating factors for stent patency in patients with malignant biliary strictures: development of a simple score model.

Authors:  Petra G A van Boeckel; Ewout W Steyerberg; Frank P Vleggaar; Marcel J M Groenen; Ben J M Witteman; Bas L A M Weusten; Han Geldof; Adriaan C I T L Tan; Marina J A L Grubben; Jan Nicolai; Peter D Siersema
Journal:  J Gastroenterol       Date:  2011-07-14       Impact factor: 7.527

10.  Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics.

Authors:  J D Vrany; P S Stewart; P A Suci
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.